Suresh Arun, Sanji Narendranath, Kamath Pallavi Mahadeva, Devendrappa Srinivas Lokikere, Hanumanthareddy Shashikala Gowdara, Maniyar Imran, Rudrappa Suresh Surappla
Post Graduate, Department of Pharmacology, JJM Medical College , Davanagere, Karnataka, India .
Associate Professor, Department of Pharmacology, JJM Medical College , Davanagere, Karnataka, India .
J Clin Diagn Res. 2016 Nov;10(11):FC14-FC16. doi: 10.7860/JCDR/2016/21743.8881. Epub 2016 Nov 1.
Thrombosis is an invariable component contributing to cardiovascular events in patients with hypertension. One of the risk factors of cardiovascular disease is increased platelet activity. One among the widely used antihypertensive agents are Angiotensin II type 1 Receptor Blockers (ARBs). Even though there are many studies involving antihypertensive agents, their antithrombotic properties remain elusive and not fully characterized.
To evaluate the anti-aggregatory effect of ARBs on platelets in-vivo.
A total of 60 subjects were included in this observational pilot study conducted in the medicine out patient department of JJM Hospital, Davanagere, Karnataka, India. Among them, 30 patients with essential hypertension attending Medicine OPD of a tertiary care hospital, who were on ARB for at least one month, were enrolled into study group. The control group consisted of 30 normotensive subjects who were not on any drug affecting platelet function. The Bleeding Time (BT) was evaluated for both the groups using Duke method of BT estimation. Data was analysed using SPSS software version 20. The test group was compared with control group using student's unpaired t-test.
The mean BT of study group was 2.488 minutes ± 0.0361 Standard Error of Mean (SEM) and that of control group was 1.998 minutes ± 0.0362 SEM. The result was statistically significant (p<0.001). The average duration of treatment was 2.933 years.
ARB have antiplatelet activity. Increase in BT in ARB group when compared with that of control group is a reflection of antiplatelet activity.
血栓形成是高血压患者发生心血管事件的一个不变因素。心血管疾病的危险因素之一是血小板活性增加。血管紧张素II 1型受体阻滞剂（ARBs）是广泛使用的抗高血压药物之一。尽管有许多关于抗高血压药物的研究，但其抗血栓特性仍然难以捉摸且未得到充分表征。
评估ARBs在体内对血小板的抗聚集作用。
本观察性试点研究共纳入60名受试者，研究在印度卡纳塔克邦达瓦纳盖雷市JJM医院的内科门诊进行。其中，30例原发性高血压患者在三级护理医院的内科门诊就诊，他们服用ARB至少1个月，被纳入研究组。对照组由30名血压正常且未服用任何影响血小板功能药物的受试者组成。两组均采用杜克出血时间（BT）估计法评估出血时间。使用SPSS 20软件进行数据分析。采用学生非配对t检验将试验组与对照组进行比较。
研究组的平均BT为2.488分钟±0.0361平均标准误（SEM），对照组为1.998分钟±0.0362 SEM。结果具有统计学意义（p<0.001）。平均治疗时长为2.933年。
ARB具有抗血小板活性。与对照组相比，ARB组BT增加反映了其抗血小板活性。
